LIVE
Ethereum Reached Record Q1 On-Chain Users and Transaction Volume: ReportMorgan Stanley's Ethereum, Solana ETFs Target 0.14% FeeCME Sues CFTC Over Kalshi Perpetual FuturesKraken Launches In-App Trading for 2,500+ Solana TokensBitcoin Rodney Pleads Guilty in $1.8B HyperFund Fraud CaseCME to Sue CFTC Over Approval of Crypto Perpetual FuturesWorld Datacentre Summit Philippines 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesARK Invest Buys $18.4 Million in Coinbase Shares Across Three ETFsWorld Datacentre Summit Malaysia 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesKentucky Files Lawsuits Against Kalshi and PolymarketEthereum Reached Record Q1 On-Chain Users and Transaction Volume: ReportMorgan Stanley's Ethereum, Solana ETFs Target 0.14% FeeCME Sues CFTC Over Kalshi Perpetual FuturesKraken Launches In-App Trading for 2,500+ Solana TokensBitcoin Rodney Pleads Guilty in $1.8B HyperFund Fraud CaseCME to Sue CFTC Over Approval of Crypto Perpetual FuturesWorld Datacentre Summit Philippines 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesARK Invest Buys $18.4 Million in Coinbase Shares Across Three ETFsWorld Datacentre Summit Malaysia 2026 Opens Sponsorship, Speaking, and Exhibition OpportunitiesKentucky Files Lawsuits Against Kalshi and Polymarket
Homepage/News/Windtree Therapeutics Delisted from Nasdaq f...
NEWS

Windtree Therapeutics Delisted from Nasdaq for Rule Noncompliance

BY Solomon M.·2 MIN READ·AUGUST 21, 2025

Windtree Therapeutics was delisted from Nasdaq due to a $1 minimum bid rule breach amid their BNB treasury strategy.

Windtree Therapeutics will be delisted from Nasdaq on August 21, 2025, after failing to meet listing criteria, impacting its ambitious treasury strategy involving Binance Coin.

KEY FINDINGS - EVIDENCE LEVEL: MULTI-SOURCE
1Key sections mapped in this report
0Internal references connected to related coverage
3External source domains cited in the article
2 minEstimated time to read the full report
Key Points:
  • Windtree’s delisting triggers significant stock drop, leadership silent.
  • Windtree shifted treasury to BNB, impacting stock negatively.
  • No adverse effect on BNB despite Windtree’s delisting.
windtree-therapeutics-delisted-from-nasdaq-for-rule-noncompliance
Windtree Therapeutics Delisted from Nasdaq for Rule Noncompliance
MAGA

The delisting highlights significant concerns surrounding distressed companies adopting digital assets without core financial stability, impacting market perceptions but not affecting Binance Coin directly.

Windtree Therapeutics Delisted from Nasdaq

Windtree Therapeutics has been delisted from Nasdaq, effective August 21, 2025, after failing to maintain the $1 minimum bid price. This delisting was communicated via a formal notification from Nasdaq on August 19, 2025, according to an official SEC filing.

The company’s leadership, including the CEO and major stakeholders, have not issued any public statements. Windtree attempted to anchor its treasury by reallocating $520 million into Binance Coin (BNB), reflecting a bold strategic shift.

Windtree’s delisting led to a 77% intraday stock drop, closing at $0.0942, marking a dramatic shift in investor confidence. Concerns grew over the company’s structural risk following its pivot to a crypto-based treasury. The decision to move shares to OTC trading signifies a significant shift in strategy for Windtree. Analysts emphasize the liquidity and regulatory risks associated with this move, reflecting broader concerns over firms adopting crypto as financial lifelines.

BNB reached a new all-time high, unaffected by Windtree’s market outcomes. There’s been no observed impact on other cryptocurrencies following Windtree’s strategic moves, underscoring the isolated reaction to this specific delisting. Analysts warn that firms adopting crypto treasuries without addressing fundamental business health remain vulnerable.

Analysts highlight structural risks of distressed firms adopting digital asset treasuries, noting forced liquidation cycles and amplified market volatility exposure… Windtree’s case underscores the limitations of rebranding via crypto exposure without addressing core financial instability, warning of regulatory and liquidity risks.

The historical persistence of regulatory and liquidity challenges in similar precedents highlights these risks. The market’s disconnect from Windtree’s actions raises questions about treasury strategies.

Disclaimer:

The content on The CCPress is provided for informational purposes only and should not be considered financial or investment advice. Cryptocurrency investments carry inherent risks. Please consult a qualified financial advisor before making any investment decisions.

SOURCE TRANSPARENCY
  • External Source - Referenced domain: buy.magacoinfinance.com
  • External Source - Referenced domain: sec.gov
  • External Source - Referenced domain: coincentral.com
  • Byline - Reported by Solomon M.
  • Coverage Desk - Primary editorial category: News
  • Media Asset - Featured image served from the WordPress media library
Windtree Therapeutics Delisted from Nasdaq for Rule Noncompliance | TheCCPress